- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Pentasa e-detail cost bar chart used a 1.5g/day maintenance dose not quantified in the SPC, unlike comparator products. PMCPA ruled the…
Actelion’s Opsumit detail aid/leavepiece used composite endpoints (morbidity–mortality; death or hospitalisation) without enough context, implying a mortality benefit. Multiple breaches were found;…
A public complaint alleged Pierre Fabre failed to disclose Javlor (vinflunine) trial results. The PMCPA ultimately ruled no breach after appeal, finding…
Janssen admitted a first-line sales manager did not take the ABPI representatives exam within 12 months of starting the role. The Panel…
At ESC 2015, Daiichi-Sankyo’s stand included a photo booth that emailed delegates their photos. PMCPA ruled the emailed photos were a gift…
Complaint alleged Tresiba was promoted to the public via a LinkedIn post generated from a press release. Panel found Novo Nordisk had…
Complaint alleged a world-renowned restaurant venue and buffet would be the main draw for an Invokana promotional meeting. Panel said venue and…
Anonymous complaint about a nurse-led consultancy. Panel found no proven breach for therapy review grants, but ruled breaches where an email linked…
Astellas admitted Code issues after three Betmiga videos with product claims appeared online via third parties. Panel ruled breaches for two Vimeo…
Complaint about a Nicorette online ad: use of an infant image and a “43% more effective” claim without absolute data. PMCPA Panel…
A GP complained about a Tresiba promo email. PMCPA found the cost comparison table and HbA1c messaging could mislead due to unclear…
AstraZeneca’s CHMP-opinion press release for benralizumab was ruled within scope of the ABPI Code and found misleading/unbalanced on efficacy and safety claims.…
Inter-company complaint about Victoza congress stand emphasising CV risk reduction. Panel found the overall message was within the type 2 diabetes context…
A leavepiece and journal ad for Bonviva used the headline claim “Building bones”. PMCPA ruled it implied a direct bone-forming (anabolic) effect,…
GSK challenged an AstraZeneca Symbicort SMART leavepiece for an unqualified ‘Rx… plus as needed’ dosing line. The Panel found it reflected the…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.